Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
NSCLC
Pharma
Boehringer's lung cancer med passes muster with the FDA
Hernexeos was cleared to treat previously treated non-small cell lung cancer patients who have HER2 tyrosine kinase domain-activating mutations.
Zoey Becker
Aug 8, 2025 3:52pm
Merus' Bizengri wins FDA nod as 1st drug to target NRG1+ cancers
Dec 4, 2024 6:55pm
BMS' Opdivo widens lung cancer reach with perioperative FDA nod
Oct 3, 2024 3:54pm
FDA's ODAC calls for revamp of perioperative NSCLC trials
Jul 25, 2024 5:00pm
Boehringer Ingelheim preps for 2 upcoming oncology launches
Jun 10, 2024 8:20am
Summit and Akeso deliver Keytruda-topping results in NSCLC
May 31, 2024 11:00am
